olfactory receptor family 5 subfamily B member 10 pseudogeneGenealiases: OR13-34 · OR13-64 · OR13-67 · OR5B10 · OR5B11 · OR5B11P
Q-omics provides the consensus-scored OR5B10P profile across patient tissues and cancer cell-line models. OR5B10P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in STAD. Among the 18 cancer types available for tumor–normal comparison, OR5B10P is differentially expressed in 1, with the highest sampling consensus in KIRC. Additionally, OR5B10P RNA expression shows 5,471 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight STAD, KIRC, and COAD as cancer lineages where OR5B10P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR5B10P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR5B10P survival associations across molecular data types. OR5B10P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR5B10P RNA expression–survival associations across cancer types. High OR5B10P expression shows unfavorable associations in STAD, THYM, LGG, SKCM, KIRC and PCPG. The STAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify STAD as the clearest survival context for OR5B10P RNA expression.
This table summarizes OR5B10P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for OR5B10P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR5B10P shows higher tumor expression in KIRC. The KIRC box plot shows higher OR5B10P RNA expression in tumor versus normal tissue (log2 FC = +0.011, t-test p = .041).
This table shows molecular features associated with OR5B10P in patient tissues and cancer cell lines. In patient samples, OR5B10P shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
